comparemela.com

Latest Breaking News On - Complete enrollment - Page 1 : comparemela.com

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
San-diego
California
Japan
Linda-marb
Us-food-drug-administration
Capricor-therapeutics-inc
Ns-pharma-inc
Nasdaq
Twitter
Capricor-company-contact
Nippon-shinyaku-co-ltd

Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Enrollment Completed in CAHptain-205 Study in Pediatric Classic Congenital Adrenal Hyperplasia (CAH)Target Enrollment Completed in CAHmelia-203 Study in Adult Classic CAHCAHmelia-204 Study in Adult Classic CAH on Track to Complete Enrollment in Early Q1 2024SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Spruce Biosci.

Javier-szwarcberg
Samir-gharib
Exchange-commission
Spruce-biosciences-inc
Linkedin
Youtube
Facebook
Nasdaq
Development-rd-expenses
Enrollment-completed
Pediatric-classic-congenital-adrenal-hyperplasia
Adult-classic

Iterum Therapeutics Reports Second Quarter 2023 Financial Results

Iterum Therapeutics Reports Second Quarter 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China
Japan
Dublin
Ireland
Chicago
Illinois
United-states
Japanese
Judy-matthews
Corey-fishman
Drug-administration
Japanese-patent-office

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment Continues to Progress in HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne.

San-diego
California
United-states
Japan
Linda-marb
Joyce-allaire
Yushi-feng
Paul-auwaerter
Philipj-gotwals
Raquel-cona
Business-development
Ns-pharma-inc

vimarsana © 2020. All Rights Reserved.